ForCast Orthopedics has closed its initial Series A equity financing, led by OrthoInnovations and Managing Partner Dr. Charles A. DeCook, to advance therapies for periprosthetic joint infection (PJI).
PJI is a rare but serious complication of joint replacements, often resistant to standard antibiotics due to bacterial biofilms. ForCast aims to tackle this with targeted antibiotic therapies delivered directly into the infected joint via its proprietary technology.
In connection with the financing, Dr. DeCook joins ForCast’s Board and management team as Chief Innovation Officer.
KEY QUOTES:
“We’re pleased to close our financing round and thrilled to have someone of the caliber of Dr. DeCook as our lead investor. Building upon our earlier successes in obtaining Orphan Drug and Qualified Infectious Disease Product designations from the FDA, we look forward to continuing that momentum as we work to bring our novel therapies to patients.”
Peter Noymer, PhD, Executive Chairman and CEO of ForCast
“After evaluating the critical unmet needs in PJI treatment, it became clear to me that ForCast’s approach has the potential to deliver best-in-class results for both patients and surgeons. My area of focus has always been delivering better treatment options to improve patient outcomes, and I believe ForCast fits that profile perfectly.”
Dr. DeCook
“We are really looking forward to leveraging Dr. DeCook’s expertise and track record as we move forward with our development programs. I believe that his involvement validates the strong potential of the unique treatment approach that we are pioneering.”
Jared Foran, MD, co-founder and Chief Medical Officer of ForCast
